Epstein Secrets

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for Ix Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop

mpetition coming next year). Copaxone Litigation Timeline (from 2O Results Slidedeck) Scenario Analysis — BofAML Daniel Lundquist EFTA00820344 Healthcare Specialist Sales Global Equities Bank of America Merrill Lynch The power of global connections"( Find all Conference Events via the Following Link: https://gems.ba

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mrn/yr in sales for Co

mpetition coming next year). Copaxone Litigation Timeline (from 2Q Results Slidedeck) Scenario Analysis — BofAML EFTA00820353 Daniel Lundquist Healthcare Specialist Sales Global Equities The power of global connectionsTM Find all Conference Events via the Following Link: https://gems.bankofamerica.com Disclaimer:

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop

mpetition coming next year). EFTA00665659 Copaxone Litigation Timeline (from 2Q Results Slidedeck) Scenario Analysis — BofAML Daniel Lundquist Healthcare Specialist Sales Global Equities Bank of America Merrill Lynch One Bryant Park I New York, 10036 I United States T: The power of global connectionsTM Find all C